top of page

Cardiovascular Innovation and Research Center - the leading provider for cardiovascular care and research

Our Mission: To develop and share knowledge that improves the care of patients around the world through innovative cardiovascular clinical research.
Cardiovascular Innovation and Research Center is an active clinical research institute, committed to providing patients with cutting edge cardiovascular research. Our patients have access to groundbreaking new cardiovascular/metabolic treatments. Our research staff has extensive experience in conducting clinical trials, as well as thorough knowledge of FDA regulations governing clinical research.Our medical professionals have operational expertise in phase II, III and IV clinical trials, and are focused in improving cardiovascular care through innovative clinical research.


Clinical research in the following areas is currently being conducted at CIRC:


  • Atrial Fibrillation (AF)

  • Antithrombotics/thrombosis

  • Coronary Artery Disease (CAD) and Coronary Atherosclerosis

  • Acute Coronary Syndrome (ACS) 

  • Deep Vein Thrombosis (DVT)

  • Heart Failure (HF)

  • Myocardial Infarction (MI)

  • Metabolic Syndrome

  • Pulmonary Embolism (PE)

  • Peripheral Artery Disease (PAD)

  • Type 2 Diabetes and Obesity

Selected Previous/Ongoing Clinical Trials


Our clinical research team is conducting a wide array of cardiovascular clinical trials, including the following:  

•    Cardiovascular Inflammation Reduction Trial  (CIRT) 
Sponsor: Brigham and Women's Hospital
Collaborator: National Heart, Lung, and Blood Institute (NHLBI)


•    A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Sponsor: Novartis Pharmaceuticals          
•    Affordability and Real-world antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS Study)
Sponsor: AstraZeneca 
Collaborator: Duke Clinical Research Institute

•    Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism (RE-COVERY DVT/PE)
Sponsor: Boehringer Ingelheim


•    Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II) 
Sponsor: Janssen Scientific Affairs, LLC 
Collaborator: Duke Clinical Research Institute

bottom of page